Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition

In the context of interventional cardiology, platelet function testing may identify patients treated with P2Y12-inhibitors at an increased risk of mortality, thrombosis and bleeding. Several whole blood point-of-care platelet function analyzers are available; however, inter-device differences have not been examined systematically. To compare three platelet function tests under standardized in vitro conditions. Healthy volunteer (n = 10) blood samples were spiked with increasing concentrations of ticagrelor (0–7500 ng/mL) and/or ASA (0–3280 ng/mL), measured on three platelet function analyzers (TEG^®6s, Multiplate^®, and VerifyNow^®) and respective Effective Concentration (EC) levels EC10, EC50 and EC90 were calculated. Repeatability was assessed in a separate group of pooled blood samples (n = 10) spiked with ticagrelor at EC10, EC50 and EC90. ASA had no impact on ADP-activated channels for all three devices. TEG^®6s was able to distinguish (p ≤ 0.05) between all ticagrelor EC zones; VerifyNow^® and Multiplate^® were able to distinguish between three and two zones, respectively. Multiplate^® showed the largest window between EC10 and EC90 (19–9153 ng/mL), followed by TEG^®6s (144–2589 ng/mL), and VerifyNow^® (191–1100 ng/mL). Drug effect models distribution of disagreements were identified for TEG^®6s (5.0%), VerifyNow^® (8.3%), and Multiplate^® (13.3%). TEG^®6s showed the smallest average coefficient of variation between EC conditions (5.1%), followed by Multiplate^® (14.1%), and VerifyNow^® (17.7%). Linear models could be generated between TEG^®6s and Multiplate^®, but not VerifyNow^®. Significant differences were found between whole blood point-of-care platelet function analyzers and the clinical impact of these differences needs to be further investigated.